Valuation Modalis Therapeutics Corporation
Stocks
4883
JP3922600006
Biotechnology & Medical Research
|
Market Closed -
Japan Exchange
10:30:00 12/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 27.00 JPY | -6.90% |
|
+3.85% | -51.79% |
Company Valuation: Modalis Therapeutics Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 63,031 | 17,753 | 9,769 | 3,916 | 7,079 | 4,700 |
| Change | - | -71.83% | -44.97% | -59.92% | 80.79% | -33.61% |
| Enterprise Value (EV) 1 | 57,610 | 12,817 | 6,836 | 2,445 | 3,504 | 1,888 |
| Change | - | -77.75% | -46.66% | -64.24% | 43.34% | -46.13% |
| P/E | -130x | -23.9x | -3.61x | -1.61x | -3.57x | -2.01x |
| PBR | 10.2x | 3.2x | 3.35x | 3x | 2x | 1.74x |
| PEG | - | -0.5x | -0x | 0.1x | 0.1x | 0.82x |
| Capitalization / Revenue | 184x | 17,753x | 244x | - | - | - |
| EV / Revenue | 168x | 12,817x | 171x | - | - | - |
| EV / EBITDA | -169x | -11x | -3.52x | -1.03x | -2.62x | - |
| EV / EBIT | -145x | -10.3x | -3.31x | -1.03x | -2.62x | -0.85x |
| EV / FCF | -54.1x | -16.3x | -4.88x | -1.72x | -3.93x | -1.34x |
| FCF Yield | -1.85% | -6.14% | -20.5% | -58% | -25.4% | -74.7% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -17 | -25.67 | -92.83 | -77.21 | -28.55 | -27.85 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 342 | 1 | 40 | - | - | - |
| EBITDA 1 | -341 | -1,162 | -1,940 | -2,369 | -1,336 | - |
| EBIT 1 | -398 | -1,239 | -2,063 | -2,370 | -1,337 | -2,211 |
| Net income 1 | -448 | -738 | -2,702 | -2,391 | -1,317 | -2,152 |
| Net Debt 1 | -5,421 | -4,936 | -2,933 | -1,471 | -3,575 | -2,812 |
| Reference price 2 | 2,212.00 | 613.00 | 335.00 | 124.00 | 102.00 | 56.00 |
| Nbr of stocks (in thousands) | 28,495 | 28,961 | 29,162 | 31,577 | 69,404 | 83,924 |
| Announcement Date | 31/03/21 | 29/03/22 | 28/03/23 | 27/03/24 | 27/03/25 | 25/03/26 |
1JPY in Million2JPY
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 20.62M | |
| 17.64x | 6.77x | 12.98x | 1.69% | 67.53B | |
| 32.85x | 8.79x | 29.04x | 0.07% | 60.74B | |
| 38.46x | 6.84x | 20.46x | 0.85% | 55.66B | |
| 46.76x | 6.33x | 30.27x | -.--% | 47.97B | |
| 35.83x | 3.38x | 14.58x | -.--% | 45.24B | |
| -21.57x | 57.33x | -23.69x | -.--% | 39.08B | |
| 35.06x | 8.67x | 22.58x | 0.37% | 35.34B | |
| 41.53x | 8.15x | 27.06x | -.--% | 33.45B | |
| -73.68x | 13.96x | -75.03x | -.--% | 26.49B | |
| Average | 16.98x | 13.36x | 6.47x | 0.33% | 41B | |
| Weighted average by Cap. | 21.93x | 12.19x | 11.38x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 4883 Stock
- Valuation Modalis Therapeutics Corporation
Select your edition
All financial news and data tailored to specific country editions
